Moschini M, et al. - Using the SEER-Medicare insurance program-linked database, researchers determined the differential influence of androgen deprivation therapy (ADT) on subsequent risk of bladder cancer (BCa) development in men with prostate cancer (PCa). They identified overall 196,914 patients who have received the diagnosis of histologically confirmed localized PCa between 2000 and 2009. Of those, 68,421 (34.7%) received ADT. The participants were followed-up for a median duration of 59 (29–95) months. Even after stratifying according to the type of treatment, no influence of ADT on the risk of developing a subsequent BCa was evident in this study.